IMGN ImmunoGen Inc

-0.13 (-0.81%)
After Hours
Last Updated: 16:16:03
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 3,566,163
Bid Price 15.60
Ask Price 16.30
News -
Day High 16.11


52 Week Range


Day Low 15.755
Company Name Stock Ticker Symbol Market Type
ImmunoGen Inc IMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.13 -0.81% 15.87 16:16:03
Open Price Low Price High Price Close Price Prev Close
16.03 15.755 16.11 15.87 16.00
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
31,571 3,566,163 $ 15.93 $ 56,812,578 - 3.605 - 20.69
Last Trade Time Type Quantity Stock Price Currency
16:31:46 priorref 9,683 $ 15.87 USD

ImmunoGen (IMGN) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


ImmunoGen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
3.95B 248.94M - 108.78M -222.93M -0.90 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ImmunoGen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IMGN Message Board. Create One! See More Posts on IMGN Message Board See More Message Board Posts

Historical IMGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.9716.1114.4715.192,898,2280.906.01%
1 Month16.0416.43514.4115.473,374,457-0.17-1.06%
3 Months18.6420.6913.8316.474,175,673-2.77-14.86%
6 Months3.7120.693.6614.126,061,46412.16327.76%
1 Year4.6820.693.60510.644,806,31611.19239.1%
3 Years3.5320.693.0958.063,481,96612.34349.58%
5 Years9.5020.691.656.693,132,6686.3767.05%

ImmunoGen Description

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now